Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVoTRIAL 2)

Date

08 Oct 2016

Session

Poster Display

Presenters

Eng-Huat Tan

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

E. Tan1, G. Banna2, R. Ramlau3, G. Ceresoli4, A. Camerini5, J. Milanowski6, M. Caruso7, P. Landreau8, J. Vedovato8, D. Kowalski9

Author affiliations

  • 1 Medical Oncology, National Cancer Center, 169610 - Singapore/SG
  • 2 Uo Di Oncologia Medica, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania/IT
  • 3 Oncology Department, Poznan University of Medical Sciences, Poznan/PL
  • 4 Uo Di Oncologia Medica, Cliniche Humanitas Gavazzeni, 24125 - Bergamo/IT
  • 5 Uoc Oncologia Medica, Ospedale Unico Versilia, 55041 - Lido di Camaiore/IT
  • 6 Department Of Pneumology, Oncology And Allergology, Medical University of Lublin, Lublin/PL
  • 7 Unità Funzionale Di Oncologia Medica, Humanitas Centro Catanese di Oncologia, 95121 - Catania/IT
  • 8 Medical Affairs Oncology, Institut de Recherche Pierre Fabre, 92654 - Boulogne/FR
  • 9 Department Of Lung Cancer And Chest Tumours, The Maria Sklodowska-Curie Institute of Oncology, Warsaw/PL
More

Resources

Abstract 2464

Background

In advanced/metastatic EGFR-positive (EGFR+) NSCLC pts progressing after EGFR-TKIs failure in first line, single-agent chemotherapy (CT) may be offered in pts who are unfit for a platinum combination. In this study, NVBo was evaluated as monotherapy in advanced NSCLC EGFR+ pts who failed to EGFR-TKIs in first line.

Methods

Phase II, multicentre, open-label, international study. Main eligibility criteria: stage IIIB/IV NSCLC, EGFR + , prior EGFR-TKI treatment failure, Karnofsky PS ≥70, no prior CT or immunotherapy. Study treatment until progression or unacceptable toxicity: NVBo 60 mg/m2 weekly for 3 weeks (first cycle), followed by 80 mg/m2 weekly for subsequent cycles in absence of grade 3/4 toxicity. The primary endpoint was the disease control rate (DCR = CR + PR + SD, RECIST 1.1).

Results

30 pts included (March 2013 - November 2014). Main pts characteristics: median age: 66.8 years (60% ≥65 years); median Karnofsky PS 90%. Adenocarcinoma 96.7%. ≥3 organs involved (53.3%). All pts harboured EGFR mutation and received prior EGFR-TKI therapy: Gefitinib 73.3%, Erlotinib 16.7%, Afatinib 10%; 33.3% of pts had ≥2 comorbidities; Total number of cycles: 166 (443 doses administered); median number of cycles: 3.5 (range 1-20); median relative dose intensity: 77.6% (range 46.8-105); dose escalation was performed in 76.7 % of pts; Disease control rate 63.3% (95% CI [43.8-80]) and 23.3% of patients with stable disease ≥6 months. Median time to treatment failure: 2.7 months (range 0.4-13.6). Median PFS of 3.3 months (95% CI [1.6-5.4]) and OS of 13.1 months (95% CI [6.1-15.8]). Grade 3/4 toxicities per pt: neutropenia 53.3%, anemia 6.7%, leukopenia 26.7%, fatigue 16.7%, nausea 3.3% and vomiting 6.7%. Three cases of febrile neutropenia reported. No grade 3/4 diarrhoea, constipation, peripheral neuropathies or alopecia.

Conclusions

NVBo as single-agent CT is a well-tolerated option in advanced EGFR+ NSCLC pts beyond failure of EGFR-TKI in first line. Its favourable tolerability profile allows a prolonged disease control in non-progressing pts.

Clinical trial identification

EUDRACT Number 2012-003361-18 Sponsor's Protocol Code Number: PM0259CA229J1.

Legal entity responsible for the study

Institut de Recherche Pierre Fabre

Funding

Institut de Recherche Pierre Fabre

Disclosure

A. Camerini: Advisory board (Roche, Pierre-Fabre, Astra Zeneca). P. Landreau: Sponsor's (Pierre Fabre Laboratory) employee. J-C. Vedovato: Sponsor's employee (Pierre Fabre). All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings